Financials in USD. Standardized financial statements.
A compact view of how Awakn Life Sciences Corp. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Revenue? | $87,373 | $1.50M | $236,037 | $0 |
| Revenue Growth? | -94.2% | +533.5% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $603,534 | $512,870 | $0 |
| Gross Profit? | $87,373 | $891,809 | -$276,833 | $0 |
| Gross Margin? | +100.0% | +59.6% | -117.3% | 0.0% |
| Operating Expenses? | $4.01M | $10.08M | $9.85M | $1.46M |
| Operating Income? | -$3.93M | -$9.19M | -$9.79M | -$840,301 |
| EBITDA? | -$3.91M | -$5.26M | -$16.08M | -$840,217 |
| Income Before Tax | -$3.67M | -$9.65M | -$16.47M | -$1.48M |
| Income Tax Expense | $0 | -$509,016 | $0 | $0 |
| Net Income? | -$5.10M | -$9.14M | -$15.95M | -$1.26M |
| EPS? | $-0.13 | $-0.36 | $-0.73 | $-0.10 |
| Diluted EPS? | $-0.18 | $-0.36 | $-0.73 | $-0.10 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality